Apple is bringing polls to Messages in iOS 26
Apple announced at WWDC 2025 on Monday that it's bringing polls to Messages in its upcoming iOS 26 update. The feature has been highly requested by users, and is one that has been long adopted by services like WhatsApp and Telegram.
The feature will allow users to vote on different things directly within group chats. For example, you could create a poll to decide where your next girls' brunch will be located, or which novel you and your book club are going to read next.
Apple shared that Apple Intelligence will be able to suggest polls based on the context of your conversations. For example, if someone messages: 'What should we eat?' Apple Intelligence will suggest starting a poll.
While this new feature is in no way groundbreaking, it's nice to see Apple catch up to other chat services and give users a better way to plan and decide things right within their group chats.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Fapon Biopharma to Showcase Differentiated Pipeline, Including Phase 1 Immunocytokine FP008, and Innovative Technology Platforms at BIO 2025
BOSTON, June 12, 2025 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the BIO International Convention 2025 (BIO 2025), taking place June 16-19 in Boston Convention & Exhibition Center. The company will exhibit at Booth #1851, presenting its differentiated pipeline, including the flagship Phase 1 immunocytokine FP008, a portfolio of promising early-stage candidates for oncology and autoimmune diseases, and its suite of proprietary technology platforms, while actively seeking global partnerships. FP008, Fapon Biopharma's lead asset, is a first-in-class immunocytokine currently in Phase 1 clinical trials, designed to address significant unmet needs in solid tumor patient refractory to anti-PD-1 therapy. The company will also feature promising preclinical candidates targeting oncology (FP010, FP011, FPE021) and autoimmune diseases (FPE022, FPE024), highlighting its expanding research capabilities. Fapon Biopharma will feature its proprietary and innovative technology platforms, engineered to overcome complex drug development challenges: Bi/Tri-TCE Platform: Human-monkey cross-reactive TCR/CD3 nanobody, enabling the design of potent multi-specific antibodies for targeted cancer immunotherapy. FILTEN™ (IL-10M Fusion Protein Platform): Overcoming IL-10 limitations for broad applications in cancer and autoimmune diseases PROTiNb™ (Proteolysis Targeting Intra-Nanobody): A pioneering platform targeting previously "undruggable" intracellular targets, demonstrating a strong competitive edge. FIND™ Mammalian Cell Display Platform: Accelerating antibody discovery by combining mammalian cell expression with high-throughput screening. "We are excited to connect with the global biopharma community at BIO 2025," said Vincent Huo, President of Fapon Biopharma. "We look forward to demonstrating the exciting progress of our internal pipeline and how our technology platforms can empower external partners to bring transformative therapy to patients faster." Engagement Opportunities:Exhibition Booth: #1851Company Presentation: Time: 11:30 a.m., Tuesday, June 17, 2025Location: Room 153A, Boston Convention & Exhibition Center To schedule a meeting in advance or during the conference, please contact our BD representatives, Max Wang ( and Liyan Gao ( or visit us at Booth #1851. Meetings can also be requested via the BIO partnering system. About Fapon Biopharma ( Fapon Biopharma specializes in discovering and developing biologics for treating cancers, autoimmune diseases and other diseases where there are unmet medical needs. Leveraging cutting-edge technologies, we have built advanced drug discovery platforms, including an antibody discovery platform based on the globally leading mammalian cell display technology, a platform for generating IL-10M fusion proteins, and a platform for developing multispecific antibodies using Fibody and nanobodies. With a differentiated pipeline of leading drug candidates, we have established capabilities that cover the entire drug development process from drug discovery, preclinical research, Chemistry, Manufacturing and Controls (CMC) to early clinical development. Committed to innovation, we strive to deliver safer, more efficacious, affordable, and accessible biologics for everyone. View original content to download multimedia: SOURCE Fapon Biopharma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
MIND Technology Inc (MIND) Q1 2026 Earnings Call Highlights: Navigating Challenges with ...
Revenue: $7.9 million for the first quarter of fiscal 2026, down approximately 18% from the same period a year ago. Gross Profit: $3.3 million, with a gross profit margin of 42% for the quarter. General and Administrative Expenses: Approximately $3.4 million for the first quarter. Research and Development Expense: $380,000 for the first quarter. Operating Loss: Approximately $658,000 for the first quarter. Adjusted EBITDA: Loss of approximately $179,000 for the first quarter. Net Loss: Approximately $970,000 for the first quarter. Cash Flow from Operations: Approximately $4.1 million, an improvement of approximately 98% sequentially. Backlog of Firm Orders: Approximately $21 million as of April 30, 2025. Cash on Hand: $9.2 million as of April 30, 2025. Warning! GuruFocus has detected 5 Warning Signs with MIND. Release Date: June 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. MIND Technology Inc (NASDAQ:MIND) reported a strong cash flow from operations of $4.1 million, indicating improved liquidity. The company has a solid backlog of firm orders amounting to approximately $21 million as of April 30, 2025, up from $16.2 million at the end of January 2025. MIND Technology Inc (NASDAQ:MIND) is strategically positioned for growth with a resilient business model, improved order visibility, and a strong demand environment. The company is expanding its facility in Huntsville, Texas, which is expected to contribute significantly to revenue through additional repair and manufacturing services. MIND Technology Inc (NASDAQ:MIND) maintains a clean, debt-free balance sheet with a simplified capital structure, enhancing financial flexibility and shareholder value. The first-quarter results were down sequentially due to a $5.5 million delay in order deliveries, impacting revenue and profit margins. General and administrative expenses increased to $3.4 million, partly due to nonrecurring costs related to restructuring and tax analysis. The company reported an operating loss of approximately $658,000 and a net loss of $970,000 for the first quarter. Adjusted EBITDA was a loss of approximately $179,000, impacted by nonrecurring expenses. MIND Technology Inc (NASDAQ:MIND) faces challenges in utilizing its $80 million in US tax loss carryforwards due to the majority of its revenue being generated outside the United States. Q: On the $5.5 million delayed delivery, have those been delivered yet? And are they mainly comprised of one or two systems? A: Partially delivered. There was one large system and a few other orders. So it's a little bit of both. It will be soon, though. - Robert Capps, President, Chief Executive Officer, Director Q: On the tax loss carryforwards, what did you determine as the amount that you reasonably have that could be used in the future? A: It's about USD 80 million of NOL carryforward roughly. - Robert Capps, President, Chief Executive Officer, Director Q: Are you seeing increased interest in your technology from industries like deep-sea mining and rare earth elements? A: Yes, existing and potential new customers are looking to use their expertise in exploration survey work, which aligns with our SeaLink product line. - Robert Capps, President, Chief Executive Officer, Director Q: Do you have any active master supply agreements with larger customers, and is this approach favorable for Mind? A: We have such agreements with some larger customers, which facilitate new business by providing a framework for general terms and conditions. - Robert Capps, President, Chief Executive Officer, Director Q: Can you provide more details on the new streamer system and customer interest? A: It's more of an enhancement of what we have, allowing us to address additional markets. I prefer not to get too detailed for competitive reasons. - Robert Capps, President, Chief Executive Officer, Director Q: How did the $5.5 million delay impact your earnings in the quarter? A: It would have added about $2 million of operating profit or gross profit, roughly $0.25 a share at the gross profit level. - Robert Capps, President, Chief Executive Officer, Director Q: How much have you invested in the Texas repair facility, and how will it impact your financials? A: We've spent roughly $0.5 million. It should generate several million dollars a year of additional revenue, helping utilize tax losses. - Robert Capps, President, Chief Executive Officer, Director Q: Can you provide more information about your arrangement with the German company [GWL]? A: It's a partnership to bring a new product concept to market, and we'll have more to say about it in the near future. - Robert Capps, President, Chief Executive Officer, Director For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
39 minutes ago
- Yahoo
NewHydrogen's Plan to Win the Green Hydrogen Race
SANTA CLARITA, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- NewHydrogen, Inc. (OTCQB: NEWH), developer of ThermoLoop™, a technology that uses water and heat to produce the world's cheapest green hydrogen, today described its plan to replace expensive electrolyzers and win the renewable hydrogen race. NewHydrogen CEO Steve Hill said, 'Today, using electrolyzers is the only commercially available way to split water to produce renewable hydrogen. Electrolyzers have dominated the headlines, but their reign may be coming to an end. The time has come to kill electrolyzers!' 'The renewable hydrogen industry's heavy bet on electrolysis is holding it back,' Mr. Hill continued. 'Why? Because electrolyzers are old tech—expensive, inefficient, and fundamentally flawed. These 200-year-old systems still depend on large amounts of electricity and face major cost and scaling challenges. Despite massive investment, they've struggled to deliver the cost reductions and reliability needed to help unlock the global hydrogen economy.' ThermoLoop is being developed to change that. Instead of electricity, ThermoLoop can use any source of heat to split water into hydrogen and oxygen, making it a fundamentally different, and a more promising approach. By addressing key limitations that have dogged electrolyzers for decades, ThermoLoop has the potential to leapfrog the current state of the art and win the green hydrogen race. At the heart of ThermoLoop is its novel materials and novel reactions that keep the process running at nearly the same temperature—eliminating the energy losses of traditional thermochemical heating and cooling cycles. The Company believes this can overcome a long-standing thermochemical challenge: how to scale without wasting energy. This approach enables continuous, 24/7 hydrogen production wherever there's heat and water. Even when using large industrial heaters powered by electricity, ThermoLoop's theoretical heat-based thermodynamic efficiency suggests it can outperform electrolyzers on a cost-per-kilogram basis. That can make ThermoLoop technology not only an alternative, but a direct threat to the electrolysis-first strategy dominating today's hydrogen buildout. Mr. Hill concluded, 'Relying on inefficient electrolyzer technology won't get us to the projected $12 trillion hydrogen economy. Other horses in the race that rely on massive tracts of land and part-time sunlight won't get us there either. In my opinion, it's ThermoLoop or bust. We believe ThermoLoop can offer a smarter path forward and has the potential to be the key to finally delivering on green hydrogen's global promise.' To watch a short explainer video about ThermoLoop™ or to learn more about NewHydrogen's mission to produce the world's cheapest green hydrogen, visit About NewHydrogen, Inc. NewHydrogen is developing ThermoLoop™ – a breakthrough technology that uses water and heat to produce the world's lowest cost green hydrogen. Hydrogen is the cleanest and most abundant element in the universe, and we can't live without it. Hydrogen is the key ingredient in making fertilizers needed to grow food for the world. It is also used for transportation, refining oil and making steel, glass, pharmaceuticals and more. Nearly all the hydrogen today is made from hydrocarbons like coal, oil, and natural gas, which are dirty and limited resources. Water, on the other hand, is an infinite and renewable worldwide resource. Currently, the most common method of making green hydrogen is to split water into oxygen and hydrogen with an electrolyzer using green electricity produced from solar or wind. However, green electricity is and always will be very expensive. It currently accounts for 73% of the cost of green hydrogen. By using heat directly, we can skip the expensive process of making electricity and fundamentally lower the cost of green hydrogen. Inexpensive heat can be obtained from concentrated solar, geothermal, nuclear reactors and industrial waste heat for use in our novel low-cost thermochemical water splitting process. Working with a world class research team at UC Santa Barbara, our goal is to help usher in the green hydrogen economy that Goldman Sachs estimated to have a future market value of $12 trillion. Safe Harbor Statement Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, the impact on the national and local economies resulting from terrorist actions, the impact of public health epidemics on the global economy and other factors detailed in reports filed by the Company with the United States Securities and Exchange Commission. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investor Relations Contact: NewHydrogen, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
